<SEC-DOCUMENT>0001140361-21-001771.txt : 20210305
<SEC-HEADER>0001140361-21-001771.hdr.sgml : 20210305
<ACCEPTANCE-DATETIME>20210121191418
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-21-001771
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Ltd
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div id="DSPFPageHeader" style="width: 100%;"></div>
  <div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze48d9bbc967d4f598ba2ea66abc08099" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 45.38%; vertical-align: top;">
            <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
          </td>
          <td style="width: 54.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45.38%; vertical-align: top;">
            <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Divakar Gupta</div>
            <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">+1 212 479 6474</div>
            <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">dgupta@cooley.com</div>
          </td>
          <td style="width: 54.62%; vertical-align: top;">
            <div style="text-indent: 6pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">*FOIA Confidential Treatment Request*</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Confidential Treatment Requested by Immunocore Holdings Limited in connection with Registration Statement on Form F-1 (File No. 333-252166)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">U.S. Securities and Exchange Commission</div>
    <div style="font-family: 'Times New Roman', Times, serif;">Division of Corporation Finance</div>
    <div style="font-family: 'Times New Roman', Times, serif;">100 F Street, N.E.</div>
    <div style="font-family: 'Times New Roman', Times, serif;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z960a950fbb554ee395daaadd78d414e3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 14.8%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Attn:</div>
          </td>
          <td style="width: 85.2%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Mr. Alan Campbell</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14.8%; vertical-align: top;">&#160;</td>
          <td style="width: 85.2%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Mr. Jeffrey Gabor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14.8%; vertical-align: top;">&#160;</td>
          <td style="width: 85.2%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Ms. Jenn Do</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14.8%; vertical-align: top;">&#160;</td>
          <td style="width: 85.2%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Ms. Mary Mast</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14.8%; vertical-align: top;">&#160;</td>
          <td style="width: 85.2%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14.8%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">RE:</div>
          </td>
          <td style="width: 85.2%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Immunocore Holdings Limited</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14.8%; vertical-align: top;">&#160;</td>
          <td style="width: 85.2%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Registration Statement on Form F-1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14.8%; vertical-align: top;">&#160;</td>
          <td style="width: 85.2%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">File No. 333-252166</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On behalf of Immunocore Holdings Limited (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), we submit this supplemental letter
      to the staff (the &#8220;<font style="font-weight: bold; font-style: italic;">Staff</font>&#8221;) of the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) in connection with the filing by Company
      of a Registration Statement on Form F-1 with the Commission on January 15, 2021 (File No. 333&#8209;252166) (the &#8220;<font style="font-weight: bold; font-style: italic;">Registration Statement</font>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Confidential Treatment Request</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">Because of the commercially sensitive nature of information contained herein, this submission is accompanied by the Company&#8217;s request for confidential
      treatment for selected portions of this letter. The Company has filed a separate copy of this letter, marked to show the portions redacted from the version filed via EDGAR and for which the Company is requesting confidential treatment. In accordance
      with 17 C.F.R. Sec.200.83(d)(1), if any person (including any governmental employee who is not an employee of the Commission) should request access to or an opportunity to inspect this letter, we request that we be immediately notified of any such
      request, be furnished with a copy of all written materials pertaining to such request (including, but not limited to, the request itself) and be given at least ten business days&#8217; advance notice of any intended release so that the Company may, if it
      deems it to be necessary or appropriate, pursue any remedies available to it. In such event, we request that you telephone the undersigned at + 1 212 479 6474 rather than rely on the U.S. mail for such notice.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0d3d92c2e6c04f27a0d7fd0d6ad44d45" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
          </td>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
            <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Two</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">Preliminary IPO Price Range</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Company advises the Staff that it preliminarily estimates a price range (the &#8220;<font style="font-weight: bold; font-style: italic;">Preliminary Price
        Range</font>&#8221;) of $[***] per share to $[***] per American Depositary Share (&#8220;<font style="font-weight: bold; font-style: italic;">ADS</font>&#8221;) for the Company&#8217;s proposed initial public offering (&#8220;<font style="font-weight: bold; font-style: italic;">IPO</font>&#8221;),


      which takes into account a proposed [***]-for-[***] stock split of the Company&#8217;s ordinary shares and non-voting ordinary shares (&#8220;<font style="font-weight: bold; font-style: italic;">Stock Split</font>&#8221;) that will be effected prior to the
      effectiveness of the Registration Statement. The Company advises the Staff that it preliminarily estimates a pre-money valuation range of approximately $[***] million to $[***] million (the &#8220;<font style="font-weight: bold; font-style: italic;">Valuation


        Range</font>&#8221;) for its proposed initial public offering (&#8220;<font style="font-weight: bold; font-style: italic;">IPO</font>&#8221;). As described in the Registration Statement, the Company plans to effect a reorganization of its outstanding share capital
      (the &#8220;<font style="font-weight: bold; font-style: italic;">Reorganization</font>&#8221;) subsequent to the effectiveness of the Registration Statement but prior to the closing of the IPO. In the Reorganization, all outstanding classes of the Company&#8217;s
      ordinary shares (its series A preferred shares, series B preferred shares, series C preferred shares and G shares, as explained in more detail below) will be exchanged for shares of a single class of ordinary shares. The exchange ratio of each
      individual class of ordinary shares will depend upon the actual pre-money valuation of the Company to be determined at pricing of the IPO.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Notwithstanding that the exact exchange ratio of each class of ordinary shares will not be known until the pricing of the IPO, the aggregate number of
      ordinary shares to be outstanding immediately prior to the issuance of the new ADSs in the IPO will have been calculated and will be set forth in the preliminary prospectus. The estimated price range for the ADSs to be offered in the IPO will be
      calculated as (a) the estimated valuation range at the time of the launch of the IPO divided by (b) the number of ordinary shares to be outstanding following the consummation of the Reorganization but prior to the issuance of the new ADSs in the IPO.
      This assumes that each ADS to be offered in the IPO will represent one ordinary share. The Company advises the Staff that the actual price range of the ADSs for the IPO will be, in accordance with Question 134.04 of the Staff&#8217;s Compliance and
      Disclosure Interpretations, no more than $2.00 per ADS, if the maximum price is $10 per ADS or less, or 20% of the maximum price per ADS, if the maximum price exceeds $10 per ADS.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Preliminary Price Range is based in part upon the Company&#8217;s prospects, prospects for the biopharmaceutical industry, the general condition of the
      securities markets and the recent market prices of, and the demand for, publicly traded shares of generally comparable companies in the biopharmaceutical industry, as well as input received from Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC
      and Jefferies LLC (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Representatives</font>&#8221;), the representatives of the underwriters for the proposed IPO. The Company notes that, as is typical in IPOs, the Preliminary Price
      Range for the Company&#8217;s IPO was not derived using a formal determination of fair value, but was determined by discussions between the Company and the Representatives based on the assessment of the foregoing factors.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Company will include a narrower bona fide price range in an amendment to the Registration Statement that will precede the commencement of the
      Company&#8217;s road show, which the Company expects to be a two-dollar range within the Preliminary Price Range. However, the parameters of the bona fide price range will be subject to then-current market conditions, continuing discussions with the
      Representatives and material business developments impacting the Company, and due to the volatility in the securities markets, in particular the volatility experienced in the market by recent IPO issuers, there is a possibility that the bona fide
      price range for the IPO may fall outside of the Preliminary Price Range. In any event, the Company confirms to the Staff that the bona fide price range will comply with Item 501(b)(3) of Regulation S-K and CD&amp;I 134.04.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="margin-bottom: 10pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
            </td>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Three</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">Summary of Recent Equity Awards</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">The Company is providing the following supplemental information to the Staff to facilitate its review process. The following table summarizes all equity
      awards granted by the Company to its employees, consultants and members of the Board during the past 12 months, after giving effect to the Stock Split:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf77381cf9d0c4d0da26f1f78e407770c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Grant Date</div>
          </td>
          <td style="width: 12.37%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Number of</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ordinary Shares</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Underlying</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Equity</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Awards</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Granted (#)</div>
          </td>
          <td style="width: 12.06%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exercise</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Price per</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Share (&#163;)</div>
          </td>
          <td style="width: 11.3%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Number</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">of Class G</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ordinary</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Shares</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Granted (#)</div>
          </td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Third-Party</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Valuation Date</div>
          </td>
          <td style="width: 11.86%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Estimated </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Fair</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Value Per</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ordinary</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Share at </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Grant </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Date (&#163;)</div>
          </td>
          <td style="width: 12.14%; vertical-align: top; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Estimated Fair</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Value Per</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ordinary</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Share at </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Grant </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Date ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">April 30, 2020</div>
          </td>
          <td style="width: 12.37%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.06%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 11.3%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">February 28, 2020</div>
          </td>
          <td style="width: 11.86%; vertical-align: bottom; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); text-align: center;">[***]</td>
          <td style="width: 12.14%; vertical-align: bottom; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[***]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">May 4, 2020</div>
          </td>
          <td style="width: 12.37%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.06%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 11.3%; vertical-align: bottom; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); text-align: center;">[***]</td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">February 28, 2020</div>
          </td>
          <td style="width: 11.86%; vertical-align: bottom; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); text-align: center;">[***]</td>
          <td style="width: 12.14%; vertical-align: bottom; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[***]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">June 3, 2020</div>
          </td>
          <td style="width: 12.37%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.06%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 11.3%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">February 28, 2020</div>
          </td>
          <td style="width: 11.86%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.14%; vertical-align: bottom; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[***]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">June 10, 2020</div>
          </td>
          <td style="width: 12.37%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.06%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 11.3%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">February 28, 2020</div>
          </td>
          <td style="width: 11.86%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.14%; vertical-align: bottom; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[***]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">October 30, 2020</div>
          </td>
          <td style="width: 12.37%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.06%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 11.3%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">October 28, 2020</div>
          </td>
          <td style="width: 11.86%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.14%; vertical-align: bottom; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[***]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">November 10, 2020</div>
          </td>
          <td style="width: 12.37%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.06%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 11.3%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">October 28, 2020</div>
          </td>
          <td style="width: 11.86%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.14%; vertical-align: bottom; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[***]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.99%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">November 16, 2020</div>
          </td>
          <td style="width: 12.37%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.06%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 11.3%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 19.26%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">October 28, 2020</div>
          </td>
          <td style="width: 11.86%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[***]</div>
          </td>
          <td style="width: 12.14%; vertical-align: bottom; background-color: #D9D9D9; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[***]</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">As described in the Registration Statement and set out in its Articles of Association, the Company has six classes of share in issue (series A preferred
      shares, series B preferred shares, series C preferred shares, G shares and ordinary shares, with G shares being further categorized into G1 and G2 with no difference in terms among the G shares other than the relevant financial hurdle, which
      determines when the G shares are entitled to participate in the distribution of proceeds on a liquidity event). The G shares do not confer any voting or dividend rights on the holders.&#160; The other classes of share rank equally with respect to voting
      rights. Holders of series A preferred shares, series B preferred shares and series C preferred shares are entitled to a non-cumulative annual 8% dividend if declared by the Company&#8217;s Board of Directors, which ranks in priority to the ordinary shares
      (the &#8220;<font style="font-weight: bold; font-style: italic;">Preference Dividend</font>&#8221;). Any Preference Dividend, if declared, is paid first to the holders of series C preferred shares, then to the holders of series B preferred shares and finally, to
      the holders of series A preferred shares.&#160; The series A preferred shares, series B preferred shares, the series C preferred shares and the ordinary shares rank equally with respect to dividends declared after the Preference Dividend.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Other than the right to receive dividends, the primary difference between the classes of shares relates to the assets to be distributed to that class in
      the event of the liquidation of the Company or with respect to liquidity event. In the event of a distribution of assets on liquidation or a return of capital, the surplus assets remaining after payment of the Company&#8217;s liabilities is to be applied <u>first</u>
      in paying to each holder of series C preferred shares an amount per share held equal to $91.05; <u>second</u> in paying to each holder of series B preferred shares an amount per share held equal to &#163;96.19; <u>third</u> in paying to each holder of
      series A preferred shares an amount per share equal to &#163;120.93; <u>fourth</u> in paying to each holder of ordinary shares an amount per share equal to &#163;64; <u>fifth</u> in paying to each holder of ordinary shares and G2 shares an amount per share
      equal to the difference between &#163;64 and &#163;170; and <u>sixth</u> in paying to each holder of ordinary shares, G1 shares and G2 shares any remaining amounts on a pro rata basis.&#160; Holders of series C preferred shares, series B preferred shares and
      series A preferred shares are entitled to receive the higher of the amount they would receive pursuant to the order of priority described above or if they converted their series C preferred shares, series B preferred shares and/or series A preferred
      shares (as the case may be) into ordinary shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The order of priority described above in relation to the distribution of assets by the Company following a liquidation of the Company or on a return of
      capital also replies to the allocation of consideration in the event of the sale of shares in the Company representing a controlling interest (as between the shareholders participating in the sale only).</div>
    <br>
    <hr style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;" align="left" noshade="noshade">
    <div style="font-family: 'Times New Roman', Times, serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>&#160;Amounts expressed in dollars based on British pounds sterling to U.S. dollar exchange rate as of the
      applicable grant date.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="margin-bottom: 10pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
            </td>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Four<br>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">In the event an employee who previously received G1 or G2 shares ceases to provide services to the Company, up to 100% of such shares can be repurchased
      by the Company for nominal value, with such percentage varying depending on the circumstances of termination.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Based on the liquidation preferences described above, the G1 shares have no value unless the liquidity event yields proceeds of at least &#163;[***] (or
      approximately $[***] based on the exchange rate as of December 31, 2020), and the G2 shares have no value unless the liquidity event yields proceeds of at least &#163;[***] (or approximately $[***] based on the exchange rate as of December 31, 2020).</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">Historical Determinations of Fair Value of Ordinary Shares</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">As there has been no public market for the Company&#8217;s ordinary shares to date, the estimated fair value of the ordinary shares has been determined by the
      Board as of the date of each share grant, with input from management, considering the Company&#8217;s most recent arm&#8217;s-length sale of its ordinary shares or third-party valuation of its ordinary shares, as well as the Board&#8217;s assessment of additional
      objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent sale of ordinary shares or third-party valuation through the date of the grant, including:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0f98e684671a4655a6c4293528574591" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">the relative liquidation preferences of the ordinary shares;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8a36e51811f74323ab2e138146e2a993" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">the progress of the Company&#8217;s research and development programs, including the status of preclinical studies and clinical trials for its product candidates;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z439359a8072148b7980db42bf825c165" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">the Company&#8217;s stage of development and commercialization and its business strategy;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb95772161710459dae356bfe56107046" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">external market conditions affecting the biotechnology industry, and trends within the biotechnology industry;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z69651f55f17f474b8decbaab510845d1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ee1e3968eed4d66a868fd91c5caf266" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">the lack of an active public market for the ordinary shares;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11316875dff54b8fb90bfdd1780b7e5d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">the likelihood of achieving a liquidity event, such as an IPO or a sale of the Company, in light of prevailing market conditions; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7c3aa65f0a842c9bb9c2374f55fafb3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The third-party valuations of the Company&#8217;s ordinary shares that the Board considered in making its determinations were prepared in accordance with the
      American Institute of Certified Public Accountants Accounting and Valuation Guide, <font style="font-style: italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</font> (the &#8220;<font style="font-weight: bold; font-style: italic;">Practice Guide</font>&#8221;), which prescribes several valuation approaches for determining the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an
      enterprise to its capital structure and, specifically, its ordinary shares.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="margin-bottom: 10pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
            </td>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Five<br>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">In accordance with the Practice Guide, the Company considered the following methods for allocating the enterprise value across its classes and series of
      capital shares to determine the fair value of its ordinary shares at each valuation date.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00390f88e5a54f4eb9d83d936e84f3c5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Option Pricing Method (OPM).</font>&#160;The OPM estimates the value of the share capital of the Company using the various inputs in the Black-Scholes
              option pricing model. The OPM treats the rights of the holders of ordinary shares as equivalent to that of call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders
              of the Company&#8217;s preferred shares, as well as their rights to participation, and the share prices of the outstanding options. Thus, the value of the ordinary shares can be determined by estimating the value of its portion of each of these
              call option rights. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceed the value of the liquidation preference at the time of a liquidity event, such as a merger or sale.
              Given the ordinary shares represent a non-marketable equity interest in a private enterprise, an adjustment to the preliminary value estimates had to be made to account for the lack of liquidity that a shareholder experiences. This adjustment
              is commonly referred to as a discount for lack of marketability (&#8220;<font style="font-weight: bold; font-style: italic;">DLOM</font>&#8221;). We have also included a discount for lack of control (&#8220;<font style="font-weight: bold; font-style: italic;">DLOC</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf92f465cab0f4362a489390427d12b22" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Probability-Weighted Expected Return Method (PWERM).</font> The PWERM is a scenario-based analysis that estimates the value per share based on the
              probability-weighted present value of expected future investment returns, considering each of the possible outcomes considered by the Company, as well as the economic and control rights of each share class.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z29ab8eab77da47fb89cb1bd11c4362f7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Hybrid Method</font>. The hybrid method is a weighted-average method that combines both OPM and PWERM. Weighting allocations are assigned to the OPM
              and PWERM methods factoring in possible future liquidity events.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">In the course of granting options and G shares as well as preparing for its IPO, the Company obtained third-party valuations of its ordinary shares as of
      February 28, 2020 and October 28, 2020. The third-party valuations resulted in the following valuations of the Company&#8217;s ordinary shares, after giving effect to the proposed Stock Split:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b1f46047fbc4465859903611990f139" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">&#163;[***] per share as of February 28, 2020; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf51190b8e59143578b0f3c99a996ecc3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif;">&#163;[***] per share as of October 28, 2020.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants'
      Accounting and Valuation Guide, <font style="font-style: italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</font>.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="margin-bottom: 10pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
            </td>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Six<br>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The third-party valuations of the ordinary shares were prepared using the hybrid method, which used market approaches to estimate the Company&#8217;s
      enterprise value. The hybrid method is a probability-weighted expected return method (&#8220;<font style="font-weight: bold; font-style: italic;">PWERM</font>&#8221;) where the equity value in one or more of the scenarios is calculated using an option-pricing
      method (&#8220;<font style="font-weight: bold; font-style: italic;">OPM</font>&#8221;). The OPM treats the various classes of shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the
      allocation among the various holders of a company's securities changes. Under this method, a class of ordinary shares has value only if the funds available for distribution to shareholders exceed the value of the liquidation preferences for that
      class at the time of the liquidity event, such as a strategic sale or a merger. The PWERM is a scenario-based methodology that estimates the fair value of each class of shares based upon an analysis of future values for the company, assuming various
      outcomes. The ordinary share value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of shares. The future value of the
      ordinary shares under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the ordinary shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">February 28, 2020 Valuation; April 2020 through June 2020 Option Grants</font>&#160;<font style="font-style: italic;">and G Shares</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The option pricing method (&#8220;<font style="font-weight: bold; font-style: italic;">OPM</font>&#8221;) was utilized for the independent third-party valuation of
      the Company&#8217;s ordinary shares as of February 28, 2020. The OPM treats a company&#8217;s security classes as call options on total equity value, with exercise prices based on the relative seniority of payments among such security classes. The value of
      junior equity interests under the OPM is based on the value of optionality over-and-above the value of securities that are senior to them in the capital structure. The Company used considered a current-value method (&#8220;<font style="font-weight: bold; font-style: italic;">CVM</font>&#8221;) based on the discounted cash flow (&#8220;<font style="font-weight: bold; font-style: italic;">DCF</font>&#8221;) Company value of &#163;[***] million to allocate the equity value among the various classes of shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">For the February 28, 2020 valuation, the Company estimated the fair value of the ordinary shares by using the PWERM. The PWERM addressed two main
      probability-weighed scenarios: (1) an exit scenario in the form of a sale of the Company, based on three trading scenarios of high, medium and low cases forecast revenues, weighted at an aggregate of [***]%; and (2) a fourth scenario where the
      Company fails to perform and is in liquidation, weighted at a low probability of [***]%. A combined DLOM and DLOC of [***]% was used for the February 28, 2020 valuation. The OPM indicated the value of the Company&#8217;s ordinary shares to be &#163;[***] per
      share as of February 28, 2020.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On April 30, 2020, the Company granted options to purchase an aggregate of [***] ordinary shares at an exercise price of &#163;[***] per share. On that same
      date, the Company also granted [***] G shares covering an aggregate of [***] ordinary shares issuable upon conversion of the G shares.&#160; The Board determined the fair value at the time of these grants was &#163;[***] per share based on a number of factors,
      including the February 28, 2020 valuation. The Company determined that there were no substantive changes in the Company&#8217;s financial position or commercial prospects that might have caused a change in fair value from the February 28, 2020 valuation.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On May 4, 2020, the Company granted options to purchase an aggregate of [***] ordinary shares at an exercise price of &#163;[***] per share.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On June 3, 2020, the Company granted options to purchase an aggregate of [***] ordinary shares at an exercise price of &#163;[***] per share.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On June 10, 2020, the Company granted options to purchase an aggregate of [***] ordinary shares at an exercise price of &#163;[***] per share. On that same
      date, the Company also granted [***] G shares covering an aggregate of [***] ordinary shares issuable upon conversion of the G shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Between May 4, 2020 and June 10, 2020, the Company engaged in extensive discussions with potential investors in connection with a potential private
      financing raise but was unable to secure a lead investor and also considered a number of potential alternatives to continue funding the Company.&#160; As a result, the Company determined that there were no substantive changes in the Company&#8217;s financial
      position or commercial prospects that might have caused a change in fair value or warranted an updated independent third-party valuation. Accordingly, the Company continued to use a fair value of &#163;[***] per ordinary share for equity grants through
      that date.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-style: italic;">October 28, 2020 Valuation; October 30, 2020 through November 2020 Option Grants</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Company obtained an updated valuation of its ordinary shares as of October 28, 2020 as it held its IPO organizational meeting on October 12, 2020,
      which gave the Company some visibility into the probability and timing of a potential IPO. However, mere intent to file a registration statement and exit via an IPO does not necessarily mean that the Company would be successful in doing so.
      Unexpected systemic events like the biotech IPO market cooling, fatigue from institutional investors, the effects of the COVID-19 pandemic, or other development setbacks could materially impact the viability of the Company's IPO or the Company&#8217;s
      aspirations to continue pursuing one. Furthermore, the Representatives had not yet provided pricing indications.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="margin-bottom: 10pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
            </td>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Seven<br>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The OPM was utilized for the independent third-party valuation of the Company&#8217;s ordinary shares as of October 28, 2020. The Company used considered a CVM
      based on the DCF Company value of &#163;[***] million to allocate the equity value among the various classes of shares. The Company estimated the fair value of the ordinary shares by using the PWERM. The PWERM addressed an exit scenario in the form of an
      IPO, based on three trading scenarios of (1) a high case of a direct IPO at &#163;[***] million, weighted at [***]%, (2) a medium case of a direct IPO at &#163;[***] million, weighted at [***%, and (3) a low case of an IPO through a special purpose acquisition
      company at &#163;[***] million, weighted at [***]%. A combined DLOM and DLOC of [***]% was used for the October 28, 2020 valuation. The OPM indicated the value of the Company&#8217;s ordinary shares to be &#163;[***] per share as of October 28, 2020.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On October 30, 2020, the Company granted options to purchase an aggregate of [***] ordinary shares at an exercise price of &#163;[***] per share.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On November 10, 2020, the Company granted options to purchase an aggregate of [***] ordinary shares at an exercise price of &#163;[***] per share.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On November 16, 2020, the Company granted options to purchase an aggregate of [***] ordinary shares at an exercise price of &#163;[***] per share.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Between October 30, 2020 and November 16, 2020, there were no substantive changes in the Company&#8217;s financial position or commercial prospects that might
      have caused a change in fair value or warranted an updated independent third-party valuation. During this time, the Company continued to face difficulty in securing a lead investor for a proposed private financing raise, including receiving feedback
      from potential investors of proposed valuations lower than the October 28, 2020 valuation. Accordingly, the Company continued to use a fair value of &#163;[***] per ordinary share for equity grants through that date.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Subsequent to November 16, 2020, the Company received positive results from the Phase 3 clinical trial of its lead product candidate, tebentafusp, which
      it publicly reported on November 23, 2020. Importantly, it was only after this information regarding its Phase 3 clinical trial was released, that the Company was able to close a private financing in December 2020 with a pre-money valuation of $[***]
      million. In the financing, the Company sold an aggregate of [***] series C preferred shares, or [***] post-split shares, at a purchase price of $[***] per share, or $[***] post-split per share, which only represents a [***]% increase from the October
      28, 2020 valuation and also partly reflects fluctuation in currency exchange rates.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">Explanation of Difference Between Fair Value of Ordinary Shares as of November 16, 2020 and the Midpoint of the Anticipated
      Preliminary Price Range</div>
    <div style="text-align: justify; text-indent: 18pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">The Company respectfully submits to the Staff that the increase in value between the November 16, 2020 option grants and the Preliminary Price Range is
      reasonable. Specifically, the Company received an independent third-party valuation of its ordinary shares as of October 28, 2020 that indicated that the fair value of the ordinary shares on that date was $[***] per share, which is only a [***]%
      discount from the bottom of the Preliminary Price Range.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">To the extent that the Company makes any further equity awards after the date of this letter but prior to the completion of the IPO, it expects that the
      exercise price per share will be no less than the midpoint of the actual price range for the IPO.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">The Company supplementally advises the Staff that the Company believes that the difference between the most recent fair market value of its ordinary
      shares for option grant purposes, as determined by the Board on November 16, 2020, and the Preliminary Price Range is in part attributable to the fact that the valuations for option grants took into account a discount for lack of marketability that
      the Company believes will continue to apply until the Company completes its IPO. In addition, the discount applicable to the November 16, 2020 option grants, as compared to the Preliminary Price Range, is supported by (1) the inherent uncertainty of
      completing a successful IPO in the near term with no weighting attributed to any other outcome for the Company&#8217;s business, such as remaining a privately-held company, being sold in a sale transaction or a liquidation of its assets in a dissolution
      scenario; (2) the possibility that the actual IPO price could be substantially lower than the Preliminary Price Range recommended by the Company&#8217;s underwriters; (3) the 180-day lock-up agreement to which the shares underlying the Company&#8217;s options
      will be subject following the IPO; (4) the Preliminary Price Range assumes the Reorganization; (5) updated market conditions used in the determination of the Preliminary Price Range after discussions with the Representatives, based on the current
      market environment and the supply and demand for such investment opportunities in the marketplace; (6) the Preliminary Price Range reflects the increase in value resulting from the Company&#8217;s positive Phase 3 clinical trial results for tebentafusp;
      (7) the completion of the series C preferred financing strengthened the Company&#8217;s balance sheet and increased the probability of success of an IPO; and (8) completion of the IPO would further strengthen the Company&#8217;s balance sheet, provide the
      Company access to public equity and enhanced operational flexibility, thereby increasing the value of the Company&#8217;s ordinary shares compared to that of a private company.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="margin-bottom: 10pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
            </td>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Eight<br>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">Based on the Preliminary Price Range, the current status of the financial markets and continued uncertainty as to whether the Company will be able to
      complete its planned IPO within the Preliminary Price Range, or at all, the Company believes that the fair market value of its ordinary shares as determined by the Board as of November 16, 2020 is consistent with the Company&#8217;s and the
      Representatives&#8217; preliminary estimates of the Preliminary Price Range, and that the prior valuations were consistent with the increasing value of the Company&#8217;s ordinary shares in connection with its progression towards an IPO.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">Conclusion</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">In light of the above, the Company respectfully submits that the per share grant date estimated fair values, as set forth in the table above under
      &#8220;Summary of Recent Equity Awards,&#8221; which have been used as the basis for determining the stock-based compensation in connection with its option grants and G Shares during the past 12 months were reasonable and appropriate for the reasons described
      herein and in the Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">We hereby further request, pursuant to Rule 418(b) under the Securities Act of 1933, as amended, the return of the unredacted version of this letter. The
      Company believes that return of the supplemental information contained in this letter will protect the interests of investors and is consistent with the provisions of the Freedom of Information Act by maintaining in confidence the potential valuation
      of the Company that may, if disseminated, negatively impact the trading in the ordinary shares of the Company following the IPO. The Company advises the Staff that it has not filed the supplemental information subject to this request in electronic
      format. Please return this letter to the Company, care of the undersigned, a responsible representative of the Company, at 55 Hudson Yards, New York, New York 10001.</div>
    <div><br>
    </div>
    <div style="text-align: center; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">****</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
          Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="margin-bottom: 10pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="margin-left: 5.4pt;"><img src="nt10016217x6_img01.jpg" height="43" width="134"></div>
            </td>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">January 21, 2021</div>
              <div style="margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif;">Page Nine<br>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif;">If you have any questions or comments with regard to this matter, please do not hesitate to contact the undersigned at +1 212 479 6474 or Courtney Thorne
      at +1 617 937 2318.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9e2d3a7e07574884ae7eaae3184313c9" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Divakar Gupta</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Divakar Gupta</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0436c3fddf5b4f8f8fabfeb6ceab64e7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 8.78%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">cc:</div>
          </td>
          <td style="width: 91.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Brian Di Donato, <font style="font-style: italic;">Immunocore Holdings Limited</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.78%; vertical-align: top;">&#160;</td>
          <td style="width: 91.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Lily Hepworth, <font style="font-style: italic;">Immunocore Holdings Limited</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.78%; vertical-align: top;">&#160;</td>
          <td style="width: 91.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Eric W. Blanchard, <font style="font-style: italic;">Cooley LLP</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.78%; vertical-align: top;">&#160;</td>
          <td style="width: 91.22%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Courtney T. Thorne, <font style="font-style: italic;">Cooley LLP</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.78%; vertical-align: top;">&#160;</td>
          <td style="width: 91.22%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Richard D. Truesdell, Jr., <font style="font-style: italic;">Davis Polk &amp; Wardwell LLP</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.78%; vertical-align: top;">&#160;</td>
          <td style="width: 91.22%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Yasin Keshvargar, <font style="font-style: italic;">Davis Polk &amp; Wardwell LLP</font></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageFooter" style="width: 100%;">
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the
        Commission pursuant to 17 C.F.R. Sec. 200.83.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157</div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com
        <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>nt10016217x6_img01.jpg
<TEXT>
begin 644 nt10016217x6_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3! T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .7^(O_ "(FI?\ ;+_T:E>#5[S\1?\ D1-2_P"V7_HU*\&KBQ/Q
MGV_#7^Z2_P 3_)!1117.?0A7T;X:_P"15T?_ *\H?_0!7SE7T;X:_P"15T?_
M *\H?_0!73AMV?,<3?PJ?J_R-2BBBNP^."BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8^QRS/(8EJE55I_@_P#)_P!>1V'PE_Y%6Z_Z_7_] 2N\K@_A+_R*MU_U^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOY1+>W4]S(%VAYI"Y ],GMR?SJO6+Q/9'KPX87VZGW+_ (/Z'T;_ ,)+H/\
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MOEZKNG:MJ.DR^9I][/;,65F$;D!B.FX=&'7@YZFFL3W1C5X8TO3J?>OU_P"
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M8G?8^/E&4).,E9H****"0HHHH **** "BBF2RQPQ/+*ZQQHI9W<X"@=23V%
M;CZXCQ1\1[+1)YK&QA^V7T?RL=V(HVP>">K$'&0,=QD$8KF_&GQ&:\Q8Z!<2
M1VXPTEVF4=SUVKT*@=SP3TZ=?.:Y:M?I$^JRS(>9*KBEZ1_S_P C4USQ#J7B
M*[6?49]^S(CC4;4C!.< ?ER<DX&2<5ET45R-MN[/JZ=.%.*A!62"BBB@L***
M* "BBB@ HHHH M:?J5[I5VMU87,EO,/XHVQD9!P1T(R!P>#7J/ACXH07/D66
MMIY,YPGVM2/+8\\N.-G;D9&23\HKR2BKA4E#8X<9EU#%QM46O?J?4-%>'>#_
M !Y<^&U^QW,;76GLV0@;#0DGDKZCJ=O'/<<Y]JLKVVU&RBO+.99K>5=R.O0C
M^A[$=J[J=136A\-F&6UL%.T]8O9]_P#(GHHHK0\X**** "BBB@#E_B+_ ,B)
MJ7_;+_T:E>#5[S\1?^1$U+_ME_Z-2O!JXL3\9]OPU_NDO\3_ "04445SGT(5
M]&^&O^15T?\ Z\H?_0!7SE7T;X:_Y%71_P#KRA_] %=.&W9\QQ-_"I^K_(U*
M***[#XX**** "BBH+V]MM.LI;R\F6&WB7<[MT _J>P'>@:3D[+<DEECAB>65
MUCC12SNYP% ZDGL*\O\ $GQ49U>VT"-HSN_X_)5&2 3G:A!X/')]3P#S6#XP
M\>7/B1?L=M&UKIZMDH6RTQ!X+>@Z';SSW/&./KCJUV](GV&5Y#&"]IBE=]NB
M]>_Y$MS<W%Y.T]U/)/,^-TDKEF.!@9)YZ5%117,?3))*R"BBB@84444 %%%%
M !1110!VOA;XBWVAK':7RM>V"*$1<@/" ?X3_$,9^4^@ ( KUW1]8LM=TV.^
ML9=\3\$'AD;NK#L1_P#7&00:^;:V?#7B6]\,ZD+JU.^)\">!CA95_H1V/;W!
M(.]*NXZ2V/ S/)*>(BZE%6G^#_X/G]Y]$450T?6++7=-COK&7?$_!!X9&[JP
M[$?_ %QD$&K]=R=]4?$3A*$G&2LT%%%%!)Y)\5M"^SW\&MPK^[N<0S\]) /E
M/7NHQP,#9[UYS7TEK6E1:WHUUILQVK.FT-S\K=5; (S@@'&><5\Y7-O+9W<U
MK.FR:%VCD7(.&!P1D<=:X<1#EE?N?=9!C?;8?V4MX?ET^[;[B*BBBL#W@KV_
MX;:[_:WAM;25LW.GXA;CK'_ >@'0%>Y^7)ZUXA6]X.UW_A'O$EO=NV+9_P!S
M<<?\LVQD]">" W')QCO6E*?)(\S-\%];PSBOB6J_R^9]!T445Z)^=!1110 4
M444 %%%% !11574M0@TK3;B_NFVPP(7;D GT R0,D\ =R10.,7)J*W9YC\6=
M9:6]M=&C93'"HGFPP)WG(4$8R"%R>O.\<=*\VJUJ6H7&JZE<7]TVZ:=R[<D@
M>@&23@#@#L *JUYE27-)L_3,!A5A</&EVW]>H4445)UCHHI)I4BB1I)'8*B(
M,EB>@ [FOI#1=*BT31K7383N6!-I;GYFZLV"3C)).,\9KRGX7^'_ .T-9?59
MX\VUE_J]R\-*>G48.T<]002IKV6NS#0LN8^,XCQ?/4CAXO2.K]?^ OS/'_BY
M<RMX@L;4OF&.U\Q5P.&9F#'/7HB_E7GU='X]N8KKQOJDD+[E#K&3@CYE158<
M^A!%<Y7-4=YMGTN6T_9X.G'R7XZA1114'<%>Q?"C2VM= N=1<,&O9<)E@043
M(! Z@[BXY]!^/CM?1'A*WBM?".DQPIM4VL<A&2?F8;F//J236^'5Y7/G^(ZS
MAA5!?:?X+7\[&S1117<?#A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445Q7Q%\4MH>EBQM)&2_NU.UXW ,* C+>N3R!^)SD5,I*
M*NS?#8>>)JQI0W9@_$CQE)YLF@Z;.OE[<7DL;<D\YBSV'KCKG'&"#YC117G3
MFYN[/T;!8.GA*2I0^;[ON%%%%2=8445U'A_P%K6O>7-Y7V2S;!\^<$;EX.57
MJW!R#P#CK3C%R=D95J]*A'GJRLCEZ*]OTKX9Z!I^Q[E)+^8;3F=L(&'7"C P
M3V;=_//5VEC:6$1BLK6"VC+;BD,80$^N!WX'Y5O'#2>[/ K\2T(NU*#E^'^?
MY'S+17U#15?5?,Y_]:/^G7_DW_ /EZBOH#4? _AS4HMCZ7! P5@KVR^45)[_
M "X!([9!_G7"Z[\*;NWS-HEQ]JC_ .>$Y"R#H.&X4]SSMP!WK.5":VU/1PV?
MX2L^67NOSV^__.QYS14MS;7%G.T%U!)!,F-T<J%6&1D9!YZ5%6)[2::N@HHH
MH&=#X/\ $\GA?5_M!1I;69=D\2M@D9X8#IN';/J1QG->]VUS%>6D-U ^^&9%
MDC;!&5(R#@\]*^8Z[SX<^+;C3M2@T6Z??87+[(MV289#TVX[,>".F3GCG/10
MJ\KY7L?.YYE?MXO$4OB6_FO\T>RT445VGQ(4444 %%%% !7D7Q(\8+?RR:#9
M;A!!+BYD)(\QUR-@']T'UZD#'3)Z'XC^+;C18(M,T]_+N[E"\DHR&BCS@;>V
M20W.<C'J01XU7+7J_81]7D.5WMBJO_;J_7_+[^P4445R'UH4444 %%=EH7PV
MUK5L2W:_V=;'^*=3YAZ]$X/4#[V.#D9KT32_AUX<TQ@YM6O) Q(:[;> ",8V
M@!2/J#U^E:PH3D>1BL[PF'?+?F?E_GL>$T5].6UM!9P+!:P1P0IG;'$@51DY
M. ..M2UK]5\SRWQ0KZ4O_)O^ ?+U%?3TL4<T3Q2HLD;J5='&0P/4$=Q7.:IX
M!\.:HIS8+:R;0HDM/W9 !S]T?*3VR0?Y4GAGT9K2XFI2=JD&O1W_ ,CP2BN\
M\0?"_4M/\R?2G^WVPR?+QB91R>G1L #IR2>%KA98I(97BE1HY$8JZ.,%2.H(
M[&L)0E%ZGNX;%T<3'FI2O_78;1114G2%=1X+\6W'AO4EBD?=IL[@3QMG"=O,
M7&3D#KCJ!CT(Y>BG&3B[HRKT(5Z;IU%=,^GHI8YHDEB=9(W4,CH<A@>A![BG
MUY%\,O%+6=Z-#O)&-O<-_HQ9QMB?DE>>S=N?O=OF)KUVO1IS4XW/SG'X*>#K
M.E+5='W044459Q!1110!R_Q%_P"1$U+_ +9?^C4KP:O>?B+_ ,B)J7_;+_T:
ME>#5Q8GXS[?AK_=)?XG^2"BBBN<^A"OHWPU_R*NC_P#7E#_Z *^<J^C?#7_(
MJZ/_ ->4/_H KIPV[/F.)OX5/U?Y&I11178?'!1110 5XG\1?%*ZYJ@L;217
ML+1CM>-R1,Y RWI@<@?B<X-=A\2_%']EZ;_9%JV+N\3][E,A83D'D\9)&._&
M>AP:\:KDQ%3["/K>'\NM_M53_MW_ #_R"BBBN4^K"BBNU\+?#J^UQ8[N^9K*
MP=0Z-@%Y@3_"/X1C/S'U! (-.,7)V1AB,32PT.>K*R./MK:XO)U@M8))YGSM
MCB0LQP,G '/2NML_AAXDN=_G16UIMQCSY@=WTV;NGOCK7L&E:+INB0&'3;..
MW4_>*C+-R2-S'DXR<9/%7ZZXX9?:/E<3Q+5D[4(V7GJ_\E^)Y=_PI[_J._\
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M%<W,5G:374[[(84:21L$X4#).!STKYRUK59=;UFZU*8;6G?<%X.U>BKD 9P
M!G'.*])^*^N206MMHL$B@7"^;<*4YVAALP>F"P;IS\H[=?)ZXL1.[Y>Q]KP[
M@O9TGB);RV]/^"_T"BBBN<^C"G11232I%$C22.P5$09+$] !W--KUOX9^$_L
MD":_=_ZZ="+>)D^XA/W^1G) XQ_">^[BZ<'.5D<6/QL,'1=26_1=V2^"_AW_
M &3.NI:P(Y;M<-! IW+$<9RW8L#P,9 QD$G&/0:**]"$%%61^>XK%U<54]I5
M=W^044451S!1110 4444 8?B3PMIWB6R>.YC6.YVXBNE0;XR,XY[KR<K[]C@
MCPG6-'O="U*2QOHMDJ<@CE77LRGN#_\ 6.""*^DJP_%/ANV\2Z1);2(OVE%+
M6TI."CXXYP?E/&1_4 C"K24U=;GMY3FTL++V=36#_#^NJ/GJBI;FWEL[N:UG
M39-"[1R+D'# X(R..M15PGWB::N@HHHH&?0'@WQ%'XBT"&9I5:]B4)=(#R&_
MO$8'#8SQQU'8UT->%_#G6&TOQ7!"TNVVO?W$@.2"Q^X<#ONP,GH&/UKW2O0H
MSYXZGYWF^"6$Q+C'X7JO\OE^04445J>6%07M[;:=92WEY,L-O$NYW;H!_4]@
M.]3UYI\6M8:."ST>*7'FYGG49!*@X09Z$$[CCGE0>.\5)<L;G7@<*\5B(T>^
M_IU/.-:U676]9NM2F&UIWW!>#M7HJY &<  9QSBJ%%%>:W=W9^EPA&$5&*LD
M%%%%!0Z**2:5(HD:21V"HB#)8GH .YKVCP7X"@T6!;W5(HY]2?#!6 9;?!R
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M;XEH<U"-7^5V^_\ X8[6BBBNT^+"O ?'>H?VCXSU%PTACA?R%60_=V#:P'/
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MTX!W)W[>PKRFBKIRY97./'85XJ@Z*ERWZVO_ )'U#17R]16_UKR/G_\ 5?\
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M%+.[G 4#J2>PKYAKDQ70^LX77\5^GZA1117*?6!1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% !1110 5R_Q%_P"1$U+_ +9?^C4KJ*R_$O\
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M5\5^,;WQ3.@=/L]G%S';*^X;L<LQP,GKCC@?B3E4JJ"\SU<MRJKC))[0ZO\
MR_K0]@\*>(_^$GL;N]6'R84NFAA4_>*!5.6[9))Z=.G/4[U<'\)?^15NO^OU
M_P#T!*[RJIMN*;.;,*4*.*G3@K),****LXSYPU_2VT77[W3B&"P2D)O8$E#R
MI)'&2I!_&LVO1OBUI7DZE9ZK&F%G0PRE8\#>O(+-W)!P,]D_+SFO-J1Y9-'Z
M9E^(^L8:%7JUKZ]0HHHJ#L.R^&VN_P!D^)%M)6Q;:AB%N.DG\!Z$]25[#YLG
MI7M]?+U>[>!_%D?B/2UBN)E_M2!?WZ;=N\9X<#N.F<=#V (KKP]3[+/DN(L
M[K%07D_T?Z?<=711174?*!1110 4444 %%%% !115+5M4MM%TNXU&[+""!<M
ML7)))P !ZDD#\:&[:E1C*<E&*NV<-\5M=^SV$&B0M^\N<33\=(P?E'3NPSP<
MC9[UY)5_6M5EUO6;K4IAM:=]P7@[5Z*N0!G  &<<XJA7FU)\\KGZ1EN#6$PT
M:?7=^O\ 6@4445!W!7T5X7TMM&\,Z?8.&62.(&168$J['<PR.,!B0/ZUX=X3
MT_\ M3Q7IEJ5C93.'=91E61?F8$8.<A2,5]$5U8:.\CY/B:O\%!>OZ+]0HHH
MKK/DPKYPU_2VT77[W3B&"P2D)O8$E#RI)'&2I!_&OH^O)/BUI7DZE9ZK&F%G
M0PRE8\#>O(+-W)!P,]D_+GQ$;QOV/H.'<1[/$ND]I+\5_3/.:***XC[@*[+X
M;:[_ &3XD6TE;%MJ&(6XZ2?P'H3U)7L/FR>E<;13C)Q=T88G#QQ%&5*>S_K\
M#ZAHKF?!7BF/Q+I'S[A?6RJER".&)'#C  PV"<=N1TP3TU>G&2DKH_,Z]&="
MHZ516:"BBBF9!1110 4444 %%%% !7G/Q6UW[/80:)"W[RYQ-/QTC!^4=.[#
M/!R-GO7;ZQK%EH6FR7U]+LB3@ <L[=E4=R?_ *YP 37SUJVJ7.M:I<:C=E3/
M.V6V+@  8  ]  !^%<]>I:/*NI]!D& =:M[>:]V/XO\ X&_W%*BBBN(^X"BB
MM[P9I7]L>*[&V9-T*/YTV8]Z[%YPPZ8) 7G^]WZ4TKNQG6JQI4Y5);)7/;/"
M^EMHWAG3[!PRR1Q R*S E78[F&1Q@,2!_6M>BBO32LK'Y=4J2J3<Y;MW^\**
M**9!R_Q%_P"1$U+_ +9?^C4KP:O>?B+_ ,B)J7_;+_T:E>#5Q8GXS[?AK_=)
M?XG^2"BBBN<^A"OHWPU_R*NC_P#7E#_Z *^<J^C?#7_(JZ/_ ->4/_H KIPV
M[/F.)OX5/U?Y&I11178?'!7@WQ"T[^SO&=YMB\N*YQ<)\V=VX?,>O'SA^/Z8
MKWFO-/B[I^ZTTW4E6,;':!VQ\[;AN4=.0-K]^_N:QQ$;POV/;R"O[+&*/22:
M_7]#RFBBBN ^]"O2?A)JD<5[?:7+*P:=5E@0M\N5SNP,_>((/ Z*?2O-JM:;
MJ%QI6I6]_:MMF@<.O) /J#@@X(X([@FJIRY9)G)C\-]:P\J7?;UZ'TO15+2=
M4MM:TNWU&T+&"=<KO7!!!P01Z@@C\*NUZ:=]3\TE&4).,E9H****"0HHHH *
M*** "BBB@ HJ"]O;;3K*6\O)EAMXEW.[= /ZGL!WK-T#Q1I?B.#?8SXE&=UO
M*0)5 (Y*Y/'(Y&1SZ\4KJ]C14:DH.HHOE74V:***9F%%%% !1110 4444 %%
M%% 'B'Q)T+^R?$C7<2XMM0S,O/23^,=2>I#=A\V!TKC:^@_&.A?\)#X;N+1%
MS<I^^M^?^6BYP.H'()7G@9SVKY\K@KPY9>I]_D>-^LX91E\4='^C_KL%%%%8
MGLCHI9(94EB=HY$8,CH<%2.A![&K&I:A<:KJ5Q?W3;IIW+MR2!Z 9). . .P
M JK11?H3RQYN:VH4444%!7=?"[1(]1U^74)@K1V"AE0\YD;.TX(Z##'L00M<
M+7T'X.T+_A'O#=O:.N+E_P!]<<_\M&QD=2.  O'!QGO6U"'-*_8\7/<7]7PK
M@G[TM%Z=?\OF;U%%%=Y\"%%%% !1110 4444 ,EBCFB>*5%DC=2KHXR&!Z@C
MN*\,\<>$Y/#FJ-+;PM_9<[?N'W;MAQRA/8]<9ZCN2#7NU07ME;:C92V=Y"LU
MO*NUT;H1_0]P>U9U*:FCTLMS&>"J\V\7NOZZGS+16SXE\-7OAG4C:W0WQ/DP
M3J,+*O\ 0CN.WN""<:O/::=F?H=*K"K!3@[IA1112+"MSP_XLU;PTS"QF4P.
MVYX)5W(QQC/J#TZ$9P,YQ6'133:=T9U:4*L7"HKI]SW'P[\1=)UR6.UF5K&]
MD;:D4AW(Y.<!7]>!U Y( S785\O5O:5XSU_1]BVVH2/"NT>3/^\3:O11GE1C
MCY2/T%=,,3_,?,XSAM2?-AI6\G_G_G]Y]!T5YCI?Q=C*A-6TU@P4YEM&R"<\
M#8QX&.^X]/?CHXOB/X6DB1VU%HV902CV\F5/H<*1D>Q-;JK!]3PJN58VD[.F
MWZ:_D=7161%XI\/RQ)(NM:>%=0P#W"J<'U!.0?8T_P#X270?^@WIO_@6G^-7
MS+N<GU>LOL/[F:E%9?\ PDN@_P#0;TW_ ,"T_P :R_\ A8OA7_H*_P#DO+_\
M32<XK=E1PF(G\--OY,ZBBO.[OXNZ8D0-EIMW-)NY69EC 'KD%N>G&*Y?4?BA
MXANY<VC06,89L+'&')!Z!BV<D>H ZFLY5X(]"CD6-JO6/+ZO_AW^![%J&I66
ME6C75_<QV\(_BD;&3@G '4G / Y->=^)/BHJ,]MH$:R#;_Q^2J< D'.U"!R.
M.3Z'@CFO,;FYN+R=I[J>2>9\;I)7+,<# R3STJ*L)XB3T6A[^#X>H4GS5GSO
M\/\ @_UH6M0U*]U6[:ZO[F2XF/\ %(V<#). .@&2>!P*JT45S[GT$8J*M%61
M[+\)?^15NO\ K]?_ - 2N\K@_A+_ ,BK=?\ 7Z__ * E=Y7HTO@1^<YM_OM3
MU"BBBM#SC(\3:)'X@T"YT]@HD9=T+M_!(/NG.#@=CCG!-?.\L4D,KQ2HT<B,
M5='&"I'4$=C7T_7D_P 5/#LD=ZFNVT3-%*H2Z(&0C# 5CST(P.@ VCNU<V(A
M=<R/I>'L=[.H\-/:6WK_ ,'\_4\VHHHKC/LPJ[I.J7.BZI;ZC:%1/ V5WKD$
M$8((]""1^-4J*$[:DRC&<7&2NF?0'ACQAIWBB)Q;[H;J)09+>0C('&2I_B7/
M&>.V0,BNAKYFLKVYTZ]BO+.9H;B)MR.O4'^H[$=Z](\/_%;_ %=OKMOZ+]J@
M'T&63\R2OT"UV4\0GI(^-S'(*E.3GAE>/;JO\_S/4:*I:=JVG:M%YFGWL%RH
M5681N"5!Z;AU4]>#CH:NUTIW/G91E!\LE9A11102%%,EECAB>65UCC12SNYP
M% ZDGL*Y#7?B3HNDYBM&_M&Y'\,##RQTZOR.A/W<\C!Q4RDHJ[-Z&%K8B7+2
MBVSJ[V]MM.LI;R\F6&WB7<[MT _J>P'>O"_&'C"Y\47NU=T.GQ-F& GDG^^W
MJW\N@[DYNN>(=2\17:SZC/OV9$<:C:D8)S@#\N3DG R3BLNN.K6<]%L?:95D
MT<(_:U=9_@O3_,****P/="BBNA\&^'9/$6OPPM$S643![IP. O\ =)R.6QCC
MGJ>QII-NR,ZU6%&FZDWHCT3X7^'_ .S]&?59X\7-[_J]R\K$.G49&X\]2" I
MKO*9%%'#$D42+'&BA41!@*!T '84^O2A%1C8_-,7B98FM*K+K_2"BBBJ.8*R
M/$VB1^(- N=/8*)&7="[?P2#[IS@X'8XYP36O12:35F73J2IS4X[K4^8)8I(
M97BE1HY$8JZ.,%2.H([&FUZ-\4/#'V:[36[*WQ!-Q=>6O"R9X<\_Q9QTQD<\
MM7G->;.+C*S/TO!XJ&*HQJQZ_@PHHHJ3J+^CZQ>Z%J4=]8R[)4X(/*NO=6'<
M'_ZXP0#7O/AKQ+9>)M-%U:G9*F!/ QRT3?U!['O[$$#YWJQ97MSIU[%>6<S0
MW$3;D=>H/]1V([UK2JN#\CR<SRJGC8W6DUL_T?\ 6A],T5YMX=^*EM)%';:[
M&T,JK@W<:[D<\\LH&5/3IG))Z"O0K2^M+^(RV5U!<QAMI>&0. ?3([\C\Z[8
MSC+8^(Q6!KX65JL;>?3[R>BBBK.0***BN;F"S@:>ZGC@A3&Z25PJC)P,D\=:
M!I-NR):H:QK%EH6FR7U]+LB3@ <L[=E4=R?_ *YP 37)>(/BAING^9!I2?;[
MD9'F9Q"IY'7JV"!TX(/#5Y=KGB'4O$5VL^HS[]F1'&HVI&"<X _+DY)P,DXK
M"I7C'1;GNX#(J]>2E67+'\7\O\R_XQ\5R^*=25Q'Y5G;[EMXR!NP<99CZG X
MZ#'U)YRBBN*3<G=GVM&C"A35.FK)!1112-0KV7X7^'_[/T9]5GCQ<WO^KW+R
ML0Z=1D;CSU(("FO._!OAV3Q%K\,+1,UE$P>Z<#@+_=)R.6QCCGJ>QKZ KIP\
M->9GR_$6.Y8K"PW>K].B_K]0HHHKL/CPHHHH Y?XB_\ (B:E_P!LO_1J5X-7
MO/Q%_P"1$U+_ +9?^C4KP:N+$_&?;\-?[I+_ !/\D%%%%<Y]"%?1OAK_ )%7
M1_\ KRA_] %?.5?1OAK_ )%71_\ KRA_] %=.&W9\QQ-_"I^K_(U****[#XX
M*H:UI46MZ-=:;,=JSIM#<_*W56P",X(!QGG%7Z*&KJS*A.4)*479H^8[FWEL
M[N:UG39-"[1R+D'# X(R..M15Z-\5M"^SW\&MPK^[N<0S\]) /E/7NHQP,#9
M[UYS7F3CRRL?IF"Q4<50C577?UZA1114G4=-X/\ &%SX7O=K;IM/E;,T /(/
M]]?1OY]#V(]TLKVVU&RBO+.99K>5=R.O0C^A[$=J^9:W/#?BG4?#5ZDEM(TE
MMNS+:LYV2 XSQV;@8;V[C(.]*MRZ/8\'-LFCBOWM+2?Y_P#!\SZ%HKE_#_CW
M1=>\N'S?LEXV!Y$Y W-P,*W1N3@#@G'2NHKMC)25T?%UJ%6A+DJQLPHHHIF(
M4444 %07M[;:=92WEY,L-O$NYW;H!_4]@.]<WK?Q"T+2(OW5RM_<%<I%:L&'
M?&Y^@&1@]3R#BO(M?\4:IXCGWWT^(AC;;Q$B)2 >0N3SR>3D\^G%8U*T8[:L
M]G 9+7Q+YIKECY[OT+_C3Q;<>)-2:*-]NFP.1!&N</V\QLX.2.F>@./4GG+:
MYN+.=9[6>2"9,[9(G*L,C!P1STJ*BN%R;=V?<T</3HTE2@O=1ZQX6^)\=RT=
MEKP6*5F")=HN$/'63GY3GN..>B@9KT:*6.:))8G62-U#(Z'(8'H0>XKYAKH_
M#7C35/#;A(G^T69P#;3,=JC.3L_NDY/MSR#Q713Q#6DCY_,>'XSO4PNC[=/E
MV_(]^HJ*VG^TVD,_E21>:BOY<J[73(SAAV([BI:[#XYIIV84444""BBB@ HH
MHH *\0^).A?V3XD:[B7%MJ&9EYZ2?QCJ3U(;L/FP.E>WU@^,="_X2'PW<6B+
MFY3]];\_\M%S@=0.02O/ SGM656'/$]/*,;]4Q*D_A>C_P _D?/E%%%>>?HH
M4444 %%%% '5_#W1)-7\4V\N&%O9,+B1QZ@_(N<$9+8XXX#8Z5[M7)?#G1UT
MOPI!,T6VYO?W\A."2I^X,CMMP<'H6/TKK:]"C#E@?GN=8OZSBG;:.B_7\0HH
MHK4\D**** "BBB@ HHHH **** *&L:/9:[ILEC?1;XGY!'#(W9E/8C_ZQR"1
M7B'BOP=>^%IT+O\ :+.7B.Y5-HW8Y5ADX/7'/(_$#WZF2Q1S1/%*BR1NI5T<
M9# ]01W%95*2GZGJ9=FE7!2LM8O=?Y=CYAHKT'Q;\-KC3]]]HBR75LS\VJJ6
MDB!QC'4N,Y]P,=>37GU<,H.+LS[O"XNCBH>TI.Z_+U"BBBI.D**** "BBB@
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M2LC\_J5)5)N<W=L****9 4444 <O\1?^1$U+_ME_Z-2O!J]Y^(O_ "(FI?\
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M?IGC K2HKKITHPV/C\?FM?&Z2TCV7Z]PHHHK4\P**** "BBB@ HHHH ****
M(KFV@O(&@NH(YX7QNCE0,IP<C(/'6O)/%'PSO;2>:[T1/M%F?F%ON_>Q\$D#
M/W@,<<[N0,'J?8**B=.,UJ=V"S"M@Y7IO1[KH?,$L4D,KQ2HT<B,5='&"I'4
M$=C3:^A?$'A/2?$JJ;Z%A.B[4GB;:ZC.<>A'7J#C)QC->::I\*];M&)L)(+^
M/< H#"-\8Y)#' &>.&/;\..="4=M3[#!Y[AJZM4?)+SV^_\ SL<+15J\TV_T
M[9]NL;FU\S.SSXF3=CKC(YZC\ZJUB>S&2DKQ=T%%%% PHHHH **EMK:XO)U@
MM8))YGSMCB0LQP,G '/2NHT_X;>)+[:7M8[2-DWJ]S(!Z<;5RP//0@=*:C*6
MR,*V)HT%^]DEZLY*NK\-^ =6U]DED1K*Q9=PN)4Y;@$;5R"P.1STZ\YXKT[P
M_P" M%T'RYO*^UWBX/GS@':W!RJ]%Y&0>2,]:ZBNF&&ZR/FL;Q'O'"KYO]%_
MG]Q0T?1[+0M-CL;&+9$G))Y9V[LQ[D__ %A@ "K]%%=:5M$?*SG*<G*3NV%%
M%%!(4444 %%%% '+_$7_ )$34O\ ME_Z-2O!J^@_&>G7>K>$KZQL8O-N9?+V
M)N"YQ(I/)('0&O)/^%=>*O\ H%?^3$7_ ,57'B(R<M$?8</XJA2PTHU)I/F>
M[2Z(Y>BNH_X5UXJ_Z!7_ ),1?_%4?\*Z\5?] K_R8B_^*K#V<^Q[OU_"?\_8
M_P#@2_S.7KZ-\-?\BKH__7E#_P"@"O&O^%=>*O\ H%?^3$7_ ,57M6AV\MGX
M?TVUG39-#:Q1R+D'#!0",CCK73AXR3=T?.\18FC5I05.:EKT:9?HHHKJ/E H
MHHH **** *&L:/9:[ILEC?1;XGY!'#(W9E/8C_ZQR"17C'B3P#JV@,\L:->V
M*KN-Q$G*\$G<N25 P>>G3G/%>[45G4I1GN>E@,TKX)VCK%]'_6A\O45[?KOP
MVT75LRVB_P!G7)_B@4>6>G5.!T!^[CDY.:\[U3X=>(],4N+5;R,*"6M&WD$G
M&-I 8GZ ]?K7'.C.)]CA,YPF(7Q<K[/3_@'*44Z6*2&5XI4:.1&*NCC!4CJ"
M.QIM9'JWN%%%% !1110 458M+&[OY3%96L]S(%W%(8RY ]<#MR/SKM]$^%>J
M7<N_5Y%L8%;E$822...F"5 (SSDX(Z5482ELCEQ&-H897JR2_/[CA;:VN+R=
M8+6"2>9\[8XD+,<#)P!STKT[PG\,FBEBO]?"ED8E;'AAD="[ X(ZG:/;)ZBN
MWT3PSI/A^+;I]HJR%=KSO\TC],Y;T. <# SVK7KKIX=+61\IF'$%2LG3P_NQ
M[]?^!^84445T'S@4444 %%%% !1110 4444 %%%4-:U6+1-&NM2F&Y8$W!>1
MN;HJY .,D@9QQFANRNRH0E.2C%7;/*?BAX@_M#64TJ"3-M9?ZS:W#2GKT.#M
M''0$$L*X.I;FYEO+N:ZG??-,[22-@#+$Y)P..M15YDY<TKGZ;@\-'#4(TH]/
MSZA1114G27]%TJ76]9M=-A.UIWVEN/E7JS8)&< $XSSBOH^**.&)(HD6.-%"
MHB# 4#H .PKSGX3:,L5E=:S(K"29C!#E2!L&"Q!S@@M@=.-AYZUZ37=AX6C?
MN?"\08SVV(]E':'Y]?\ (****W/!"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,:Y\)>'KJ!H9-&LE5L9,4(C;KGAEP1^!K&O/AAX;N=GD
MQ7-IMSGR)B=WUW[NGMCK7945+A%[HZJ>.Q-/X*C7S9P?_"I=!_Y^]2_[^)_\
M11_PJ70?^?O4O^_B?_$5WE%3[*'8W_M;&_\ /QG!_P#"I=!_Y^]2_P"_B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT8X:/75_H%%%%=9\@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
